Bessemer Group Inc. Sells 8,966 Shares of Bruker Corporation $BRKR

Bessemer Group Inc. cut its position in shares of Bruker Corporation (NASDAQ:BRKR) by 57.7% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,572 shares of the medical research company’s stock after selling 8,966 shares during the period. Bessemer Group Inc.’s holdings in Bruker were worth $270,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Wesleyan Assurance Society boosted its stake in Bruker by 62.9% during the second quarter. Wesleyan Assurance Society now owns 285,000 shares of the medical research company’s stock valued at $11,742,000 after buying an additional 110,000 shares during the last quarter. Nisa Investment Advisors LLC boosted its stake in Bruker by 377.5% during the second quarter. Nisa Investment Advisors LLC now owns 616 shares of the medical research company’s stock valued at $25,000 after buying an additional 487 shares during the last quarter. Brighton Jones LLC bought a new position in Bruker during the second quarter valued at approximately $376,000. Focus Partners Advisor Solutions LLC boosted its stake in Bruker by 101.8% during the second quarter. Focus Partners Advisor Solutions LLC now owns 16,069 shares of the medical research company’s stock valued at $662,000 after buying an additional 8,105 shares during the last quarter. Finally, State of New Jersey Common Pension Fund D boosted its stake in Bruker by 39.0% during the second quarter. State of New Jersey Common Pension Fund D now owns 51,828 shares of the medical research company’s stock valued at $2,135,000 after buying an additional 14,547 shares during the last quarter. 79.52% of the stock is owned by institutional investors.

Bruker Trading Down 0.6%

Shares of NASDAQ BRKR opened at $38.71 on Tuesday. The company has a debt-to-equity ratio of 1.31, a quick ratio of 0.70 and a current ratio of 1.61. The business’s 50 day moving average price is $34.52 and its 200-day moving average price is $36.99. Bruker Corporation has a fifty-two week low of $28.53 and a fifty-two week high of $64.64. The company has a market cap of $5.87 billion, a price-to-earnings ratio of 74.44, a PEG ratio of 5.31 and a beta of 1.20.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings results on Monday, November 3rd. The medical research company reported $0.45 earnings per share for the quarter, topping the consensus estimate of $0.33 by $0.12. Bruker had a return on equity of 17.89% and a net margin of 2.31%.The firm had revenue of $860.50 million for the quarter, compared to the consensus estimate of $847.40 million. During the same period in the prior year, the business posted $0.60 earnings per share. The company’s revenue for the quarter was down .5% on a year-over-year basis. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. On average, sell-side analysts expect that Bruker Corporation will post 2.69 earnings per share for the current year.

Bruker Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, October 3rd. Stockholders of record on Tuesday, September 23rd were issued a $0.05 dividend. This represents a $0.20 annualized dividend and a dividend yield of 0.5%. The ex-dividend date was Tuesday, September 23rd. Bruker’s dividend payout ratio is presently 38.46%.

Insider Buying and Selling at Bruker

In other news, Director Cynthia M. Friend sold 3,535 shares of the stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $32.25, for a total value of $114,003.75. Following the sale, the director directly owned 18,016 shares in the company, valued at approximately $581,016. This represents a 16.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 27.30% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on BRKR. Barclays dropped their price target on Bruker from $43.00 to $40.00 and set an “overweight” rating for the company in a research note on Thursday, October 2nd. Stifel Nicolaus set a $40.00 price objective on Bruker and gave the company a “hold” rating in a research note on Tuesday, August 5th. Citigroup lowered their price objective on Bruker from $40.00 to $38.00 and set a “neutral” rating for the company in a research note on Monday, August 4th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Bruker in a research note on Wednesday, October 8th. Finally, Wells Fargo & Company lowered their price objective on Bruker from $60.00 to $50.00 and set an “overweight” rating for the company in a research note on Tuesday, August 5th. Five research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Bruker has an average rating of “Hold” and an average target price of $51.00.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.